

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Confirmation No.: 4136

BLAKE et al

Atty. Ref.: MJW-39-187

Serial No. 09/367,261

TC/A.U.: 1625

Filed: August 10, 2001

Examiner: Dentz, B.

For: DRUG TARGETING

* * * * *

May 14, 2010

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**Office of Initial Patent Examinations
Filing Receipt Corrections**

Sir:

REQUEST FOR CORRECTION OF FILING RECEIPT

Enclosed is a copy of the Filing Receipt for the above-identified application which omits reference to foreign applications. Under the heading "Foreign Applications", it should read

United Kingdom	9703002.7	02/13/1997
United Kingdom	9712090.1	06/10/1997

A copy of the face page of the published PCT application from which this case derives is attached. The correction is shown on the attached marked-up copy of the filing receipt. Please note your records accordingly. Correction of same is respectfully requested.

BLAKE et al
Serial No. 09/367,261

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: /Mary J. Wilson/
Mary J. Wilson
Reg. No. 32,955

MJW:tat
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/367,261	08/10/2001	1642	1190	39-187	1	25	2

CONFIRMATION NO. 4136

FILING RECEIPT



0C000000007653507

Nixon & Vanderhye
8th Floor
1100 North Glebe Road
Arlington, VA 22201-4714

Date Mailed: 03/28/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

David Blake, Buckinghamshire, UNITED KINGDOM;
Declan Naughton, South Gloucestershire, UNITED KINGDOM;
Ged Adams, Oxford, UNITED KINGDOM, Deceased;
Ian Stratford, Darbyshire, UNITED KINGDOM;
Christopher Morris, Wiltshire, UNITED KINGDOM;
Mohammed Jaffar, Manchester, UNITED KINGDOM;
Matthew Naylor, Hertfordshire, UNITED KINGDOM;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/GB98/00461 02/13/1998

Foreign Applications

United Kingdom 9703002.7 02/13/1997
United Kingdom 9712090.1 06/10/1997
Projected Publication Date: Not Applicable, filed prior to November 29, 2000

Non-Publication Request: No

Early Publication Request: No

Title

Drug targeting

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/48	A1	(11) International Publication Number: WO 98/35701 (43) International Publication Date: 20 August 1998 (20.08.98)
<p>(21) International Application Number: PCT/GB98/00461</p> <p>(22) International Filing Date: 13 February 1998 (13.02.98)</p> <p>(30) Priority Data: 9703002.7 13 February 1997 (13.02.97) GB 9712090.1 10 June 1997 (10.06.97) GB</p> <p>(71) Applicant (for all designated States except US): THERAMARK LIMITED [GB/GB]; 90 Fetter Lane, London EC4A 1JP (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BLAKE, David [GB/GB]; 52 Ormonde Terrace, London NW8 7LR (GB). NAUGHTON, Declan [IE/GB]; 7 Angel Cottages, Woodhatch Road, Reigate RH2 7LJ (GB). ADAMS, Ged [GB/GB]; 59 Ladder Hill, Wheatley, Oxford OX33 1HY (GB). STRATFORD, Ian [GB/GB]; Bretton Cottage, Bretton, Eyam, Sheffield S30 1HH (GB). MORRIS, Christopher [GB/GB]; 36 Boundary Road, Chippenham, Wiltshire SW15 3NN (GB). JAFFAR, Mohammed [GB/GB]; 12 Everett Court, Everett Road, Withington, Manchester M20 3DT (GB). NAYLOR, Matthew [GB/GB]; 16 The Firs, Hammondstreet Road, West Cheshunt, Hertfordshire EN7 6UD (GB).</p>	<p>(74) Agent: ATKINSON, Peter, Birch; Marks & Clerk, Sussex House, 83-85 Mosley Street, Manchester M2 3LG (GB).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: DRUG TARGETING</p> <p>(57) Abstract</p> <p>The invention provides a method of targeting a drug to areas of hypoxic and/or ischemic tissue within the body in which the desired drug species is linked to a non-cytotoxic bioreductive carrier. Also provided by the invention are novel bioreductive conjugates comprising a non-cytotoxic bioreductive moiety with linked-thereto at least one therapeutic agent. The compounds of the invention are particularly suitable for the treatment of rheumatoid arthritis and other arthritic conditions, diabetes, atherosclerosis, stroke, sepsis, Alzheimer's disease and other neurological disorders, cancer, kidney disease, digestive diseases, liver disease, chronic periodontitis or ischemia following tissue transplantation.</p>		